PMID- 36197174
OWN - NLM
STAT- MEDLINE
DCOM- 20221007
LR  - 20221011
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 38
DP  - 2022 Sep 23
TI  - Efficacy and safety of different doses of baricitinib for rheumatoid arthritis: A 
      Bayesian network meta-analysis.
PG  - e30676
LID - 10.1097/MD.0000000000030676 [doi]
LID - e30676
AB  - BACKGROUND: To evaluate the comparative efficacy and safety of baricitinib with 
      different dosages in patients with rheumatoid arthritis (RA). METHODS: PubMed, 
      Embase, and the Cochrane Library were retrieved by computer to gather randomized 
      controlled trials (RCTs) of baricitinib for RA from their beginning to September 
      2021. After 2 researchers independently screened the literature and extracted the 
      data, the risk of bias of included RCTs was assessed, and Bayesian network 
      meta-analysis was performed by GeMTC0.14.3 and Stata15.1 software. RESULTS: Ten 
      publications reporting 9 RCTs were included, with 4129 patients randomized to 
      receive 1 of the 7 interventions. Seven interventions were baricitinib 1 
      mg + conventional disease-modifying antirheumatic drugs (cDMARD), baricitinib 2 
      mg + cDMARD, baricitinib 4 mg + cDMARD, baricitinib 8 mg + cDMARD, baricitinib 
      4 mg, placebo + cDMARD, and cDMARD. In the efficacy outcomes at 12 weeks, nearly 
      all doses of baricitinib with or without cDMARD were superior to placebo plus 
      cDMARD and baricitinib 8 mg combined with cDMARD might have the best curative 
      effect in most outcomes. In the efficacy outcomes at 24 weeks, all doses of 
      baricitinib with or without cDMARD were superior to placebo plus cDMARD and 
      baricitinib 4 mg monotherapy might have the best curative effect in most 
      outcomes. The intervention with the highest incidence of adverse events (AEs) 
      might be baricitinib 8 mg combined with cDMARD, and the intervention with the 
      highest incidence of infections might be baricitinib 4 mg combined with cDMARD. 
      CONCLUSIONS: Baricitinib 8 mg combined with cDMARDs was suitable for short-term 
      control of RA symptoms, and baricitinib 4 mg was more effective for treating RA 
      over a longer period of time. But attention should be paid for the risk of 
      baricitinib at 4 to 8 mg in clinical application due to the high incidence of AEs 
      and infections.
CI  - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Haikun, Wang
AU  - Haikun W
AUID- ORCID: 0000-0002-3049-3454
AD  - Department of Pharmacy, The Affiliated Bozhou Hospital of Anhui Medical 
      University (Bozhou People's Hospital), Bozhou, China.
FAU - Na, Wu
AU  - Na W
AD  - Department of Pharmacy, The Affiliated Bozhou Hospital of Anhui Medical 
      University (Bozhou People's Hospital), Bozhou, China.
FAU - Dan, Su
AU  - Dan S
AD  - Department of Pharmacy, The First Affiliated Hospital of University of Science 
      and Technology of China, Hefei, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Azetidines)
RN  - 0 (Purines)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - ISP4442I3Y (baricitinib)
SB  - IM
MH  - *Antirheumatic Agents/adverse effects
MH  - *Arthritis, Rheumatoid/chemically induced/drug therapy
MH  - *Azetidines/adverse effects
MH  - Humans
MH  - Network Meta-Analysis
MH  - Purines
MH  - Pyrazoles
MH  - Randomized Controlled Trials as Topic
MH  - Sulfonamides
MH  - Treatment Outcome
PMC - PMC9509125
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2022/10/06 06:00
MHDA- 2022/10/12 06:00
PMCR- 2022/09/23
CRDT- 2022/10/05 10:01
PHST- 2022/10/05 10:01 [entrez]
PHST- 2022/10/06 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/09/23 00:00 [pmc-release]
AID - 00005792-202209230-00020 [pii]
AID - 10.1097/MD.0000000000030676 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Sep 23;101(38):e30676. doi: 
      10.1097/MD.0000000000030676.